by MFRF_Admin | Nov 9, 2020
AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseases Represents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) — Axovant Gene...
by MFRF_Admin | Oct 15, 2020
Barry Byrne, M.D., Ph.D., receives “See The Light” Award from the Mathew Forbes Romer Foundation By: Tyler Francischine Oct. 15, 2020 — For families facing a devastating diagnosis of pediatric neurodegenerative genetic disease, Barry Byrne, M.D., Ph.D., provides a...
by MFRF_Admin | Feb 10, 2020
Boca Raton Award Program Honors the Achievement BOCA RATON February 10, 2020 — The Mathew Forbes Romer Foundation Inc has been selected for the 2020 Best of Boca Raton Award in the Education & Research Foundation category by the Boca Raton Award Program....
by MFRF_Admin | Jan 18, 2020
South Florida-Based Organization Hosts Annual “Sweetness and Laughter” Gala & “See the Light” Awards Ceremony March 15th at the Broward Center for the Performing Arts Boca Raton, FL, Jan. 17, 2020 – Twenty-two years after The Mathew Forbes Romer Foundation, or...
by MFRF_Admin | Dec 13, 2019
Linda Meran and Carole Romer from the MFRF Board had the pleasure of representing the Foundation at the FIU Nicole Wertheim College of Nursing & Health Sciences Donor Wall Unveiling & Holiday Celebration. The beautiful Donor Wall was revealed after several...
by MFRF_Admin | Nov 18, 2019
AXOVANT GENE THERAPIES RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR AXO-AAV-GM1 FOR THE TREATMENT OF GM1 GANGLIOSIDOSIS NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company...
